

## Nuvocept™: Addressing a huge public health priority in the post-Roe world



- Recent Roe v. Wade development makes the need for highly effective birth control more urgent than ever. To address this need, ARSTAT develops the first-ever oral contraceptive for women with above-normal weight.
- Twenty million US women with elevated BMI search for reliable birth control. Hormonal contraceptives (pills, patches, and rings) do not work well in this population due to poor efficacy and troublesome side effects. The Arstat's lead product – Nuvocept™ – will return the pill to these women as a trusted and safe option.
- At the pre-IND meeting, the FDA recognized the unmet need, accepted Nuvocept efficacy and safety projections, confirmed its **Phase III-ready** status, and endorsed a pathway to an **unprecedented label for women with high BMI**. Protected by **seven US patents and an EU patent**, Nuvocept is < \$20M and 3.5 years away from FDA approval. Top experts consider Nuvocept a \$1-2B/year US opportunity. Strong ex-US sales are also expected.
- The patents are authored by the Founder, Arkady Rubin, Ph.D., a 34-year pharma veteran (J&J, Pfizer), a co-inventor of Ortho Tri-Cyclen Lo, one of the best US pills with sales translated into \$1.8B/year in today's market.
- Nuvocept will be advanced by a highly experienced team with a strong track record in women's health.

## Other Arstat Products



- Premring™ (Phase IIb asset)** – **First-in-category** vaginal ring for uterine fibroids & endometriosis (14 million US women). Drug delivery directly to affected tissues could be a **breakthrough solution**. **Three US patents**
- Enhanta™ (Phase IIb asset)**– **First-in-category** single non-hormonal therapy for painful and heavy menstrual periods (>25 million US women). A likely first-line for a common disorder. **Four US patents**
- Ducept™ (Phase III-ready)**– **First oral contraceptive** designed for women with cardiovascular risk factors. The safest option for >2 million US normal-weight pill users; **minimal R&D costs**. **A US patent and an EU patent**

## Current Funding Needs



- Arstat raises a \$1M bridge financing round ahead of a planned IPO in Q1 of 2026 at a valuation that will likely produce at least a 5-6x ROI in a year. The investors in this round are expected to own 5% of the public company.
- The company will use the proceeds to finalize the team and the BoD, conduct another pre-IND meeting, assemble one IND application, select vendors for the Phase III study, and support an optional private placement.

## Business Model: Roadmap and Strategic Objectives



<b>1 Complete the \$1M bridge financing round</b> Continue R&D and support pre-IPO activities	<b>2 Possible IPO (near-term exit in ≈1 year): 5-6x ROI</b> \$150-200M post-IPO valuation target
<b>3 Complete planned programs (3-3.5 years)</b> Advance Nuvocept/Ducept up to the FDA approval. Enhanta is close to approval, Premring is in Phase III.	<b>4 EXIT (3.5 – 4 years): 25-30x ROI</b> Assuming <50% of the portfolio Net Present Value (NPV) after the completion of the planned R&D activities

***We are looking for executives (including a permanent CEO and a Chairman of the Board)***

Please visit [www.arstatinfo.com](http://www.arstatinfo.com)  
or Contact:



**Arkady Rubin, PhD, Founder,  
President / CSO**  
**E-mail: [arubin@arstatinc.com](mailto:arubin@arstatinc.com)**  
**Tel: (347)385-0878**